AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance to $67.6 billion highlight growth momentum. Risks include declining sales of Humira and Imbruvica and significant debt, but Wall Street remains optimistic with a bull case target of $297. AbbVie is positioned between peers Merck and Eli Lilly in valuation and growth prospects, with future gains hinging on new drug launches and patent defenses.
AbbVie trades at USD 277.34 on Pluang as of Oct 12, 2026 18:12 WIB, up 0.31% for the day. Its market cap stands at $488.55 billion, with a dividend yield of 2.5%. Compared to peers, Merck is priced at USD 145.64 and Eli Lilly at USD 1,180.47, showing AbbVie’s strong position in the health sector.
